Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 517 publications
The Comparative Effectiveness of Carvedilol Versus Other Nonselective β-Blockers in Cirrhosis.
Journal: Annals of internal medicine
Published: July 06, 2026
Safety of withdrawal of pharmacological treatment after recovery from HER2 therapy-related cardiac dysfunction: the HER-SAFE trial.
Journal: European heart journal
Published: July 06, 2026
Letter: HBsAg Loss After COVID-19 Vaccination: Implications for HBV Screening, Immunity Monitoring, and Health Worker Protection in LMICs. Authors' Reply.
Journal: Alimentary pharmacology & therapeutics
Published: June 21, 2026
Temporal Association Between COVID-19 Vaccination and HBsAg Loss in Chronic Hepatitis B Infection: An Interrupted Time Series Analysis.
Journal: Alimentary pharmacology & therapeutics
Published: April 16, 2026
A [68Ga]-labeled PDGFRβ-targeting peptide PET probe for assessing MASH-related fibrosis in diet-induced preclinical models and human liver specimens.
Journal: Biochemical pharmacology
Published: April 14, 2026
Erratum: Burden of fatty liver and hepatic fibrosis in persons with HIV: A diverse cross-sectional US multicenter study.
Journal: Hepatology (Baltimore, Md.)
Published: March 04, 2026
Development and psychometric evaluation of the Liver Disease Stigma Scale (LDSS).
Journal: JHEP reports : innovation in hepatology
Published: February 21, 2026
Correspondence to editorial on "Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis".
Journal: Clinical and molecular hepatology
Published: January 12, 2026
Bile salt hydrolase activity as a rational target for MASLD therapy.
Journal: Gut microbes
Published: January 02, 2026
Reaffirming the role of SGLT2 inhibitors in slowing fibrotic progression in MASLD: Correspondence to editorial on "Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis".
Journal: Clinical and molecular hepatology
Published: December 27, 2025
GLP-1RA plus SGLT2i combination therapy and liver fibrosis progression in MASLD with type 2 diabetes.
Journal: Hepatology communications
Published: November 30, 2025
Glucagon-Like Peptide-1 Receptor Agonist Use and Liver-Related Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes in the All of Us Research Program.
Journal: The American journal of gastroenterology
Published: October 06, 2025
Last Updated: 09/26/2026